Emerging roles for the pH-sensing G protein-coupled receptors in response to acidic stress

Edward J Sanderlin¹
Calvin R Justus¹
Elizabeth A Krewson²
Li V Yang¹,²

¹Department of Internal Medicine, Brody School of Medicine, East Carolina University, Greenville, NC, USA; ²Department of Anatomy and Cell Biology, Brody School of Medicine, East Carolina University, Greenville, NC, USA

Abstract: Protons (hydrogen ions) are the simplest form of ions universally produced by cellular metabolism including aerobic respiration and glycolysis. Export of protons out of cells by a number of acid transporters is essential to maintain a stable intracellular pH that is critical for normal cell function. Acid products in the tissue interstitium are removed by blood perfusion and excreted from the body through the respiratory and renal systems. However, the pH homeostasis in tissues is frequently disrupted in many pathophysiologic conditions such as in ischemic tissues and tumors where protons are overproduced and blood perfusion is compromised. Consequently, accumulation of protons causes acidosis in the affected tissue. Although acidosis has profound effects on cell function and disease progression, little is known about the molecular mechanisms by which cells sense and respond to acidic stress. Recently a family of pH-sensing G protein-coupled receptors (GPCRs), including GPR4, GPR65 (TDAG8), and GPR68 (OGR1), has been identified and characterized. These GPCRs can be activated by extracellular acidic pH through the protonation of histidine residues of the receptors. Upon activation by acidosis the pH-sensing GPCRs can transduce several downstream G protein pathways such as the Gq and G12/13 pathways to regulate cell behavior. Studies have revealed the biological roles of the pH-sensing GPCRs in the immune, cardiovascular, respiratory, renal, skeletal, endocrine, and nervous systems, as well as the involvement of these receptors in a variety of pathologic conditions such as cancer, inflammation, pain, and cardiovascular disease. As GPCRs are important drug targets, small molecule modulators of the pH-sensing GPCRs are being developed and evaluated for potential therapeutic applications in disease treatment.

Keywords: acidosis, GPCR, GPR4, GPR65 (TDAG8), GPR68 (OGR1)

Introduction

Cellular metabolism produces acid as a byproduct. Metabolism of each glucose molecule by glycolysis generates two pyruvate molecules. Under anaerobic conditions the metabolism of pyruvate results in the production of the glycolytic end product lactic acid, which has a pKa of 3.9. Lactic acid is deprotonated at the carboxyl group and results in one lactate ion and one proton at the physiological pH. Under aerobic conditions pyruvate is converted into acetyl-CoA and CO₂ in the mitochondria. CO₂ in water forms a chemical equilibrium of carbonic acid and bicarbonate, an important physiological pH buffering system. The body must maintain suitable pH for proper physiological functions. Some regulatory mechanisms to control systemic pH are respiration, renal excretion, bone buffering, and metabolism.¹⁻⁴ The respiratory system can buffer the blood by excreting carbonic acid as CO₂ while the kidney responds to decreased circulatory pH by excreting protons and electrolytes to stabilize the
physiological pH. Bone buffering helps maintain systemic pH by Ca\(^2+\) reabsorption and mineral dissolution. Collectively, it is clear that several biological systems require tight regulation to maintain pH for normal physiological functions. Cells utilize vast varieties of acid-base transporters for proper pH homeostasis within each biological context.\(^5\)–\(^8\) Some such transporters are H\(^+\)-ATPase, Na\(^+\)/H\(^+\) exchanger, Na\(^+\)-dependent HCO\(_3\)/Cl\(^-\) exchanger, Na\(^+\)-independent anion exchanger, and monocarboxylate transporters. Cells can also maintain short-term pH homeostasis of the intracellular pH by rapid H\(^+\) consuming mechanisms. Some such mechanisms utilize metabolic conversions that move acids from the cytosol into organelles. Despite these cellular mechanisms that tightly maintain proper pH homeostasis, there are many diseases whereby pH homeostasis is disrupted. These pathological conditions are characterized by either local or systemic acidosis. Systemic acidosis can occur from respiratory, renal, and metabolic diseases and septic shock.\(^1\)–\(^4\),\(^9\) Additionally, local acidosis is characterized in ischemic tissues, tumors, and chronically inflamed conditions such as in asthma and arthritis caused by deregulated metabolism and hypoxia.\(^10\)–\(^15\)

Acidosis is a stress for the cell. The ability of the cell to sense and modulate activity for adaptation to the stressful environment is critical. There are several mechanisms whereby cells sense acidosis and modulate cellular functions to facilitate adaptation. Cells can detect extracellular pH changes by acid sensing ion channels (ASICs) and transient receptor potential (TRP) channels.\(^16\) Apart from ASIC and TRP channels, extracellular acidic pH was shown to stimulate inositol polyphosphate formation and calcium efflux.\(^17,18\) This suggested the presence of an unknown cell surface receptor that may be activated by a certain functional group, namely the imidazole of a histidine residue. The identity of the acid-activated receptor was later unmasked by Ludwig et al as a family of proton-sensing G protein-coupled receptors (GPCRs). This group identified human ovarian cancer GPCR 1 (OGR1) which upon activation will produce inositol phosphate and calcium efflux through the G\(_q\) pathway.\(^19\) These pH-sensing GPCR family members, including GPR4, GPR65 (TDAG8), and GPR68 (OGR1), will be discussed in this review (Figure 1). The proton-sensing GPCRs sense extracellular pH by protonation of several histidine residues on their extracellular domain. The activation of these proton-sensing GPCRs facilitates the downstream signaling through the G\(_q/11\), G\(_s\), and G\(_{12/13}\) pathways. Their expression varies in different cell types and play critical roles in sensing extracellular acidity and modulating cellular functions in several biological systems.

**Role for the pH-sensing GPCRs in the immune system and inflammation**

Acidic pH is a main characteristic of the inflammatory loci.\(^14,20,21\) The acidic microenvironment in inflamed tissue is predominately due to the increased metabolic demand from infiltrating immune cells, such as the neutrophil. These immune cells increase oxygen consumption and glucose...
uptake for glycolysis and oxidative phosphorylation. When oxygen availability is limited, cells often undergo anaerobic glycolysis. This process generates increasing amounts of lactic acid, thereby creating a local acidic microenvironment within the inflammatory loci. This presents a role for the pH-sensing GPCR GPR65 (TDAG8) in inflammation and immune cell function. TDAG8 was originally identified by cloning as an orphan GPCR which was observed to be upregulated during thymocyte apoptosis. GPR65 (TDAG8) is predominately expressed in lymphoid tissues such as the spleen, lymph nodes, thymus, and leukocytes. It was demonstrated that GPR65 inhibited pro-inflammatory cytokine secretion, which includes IL-6 and TNF-α, in mouse peritoneal macrophages upon activation by extracellular acidification. This cytokine inhibition was shown to occur through the G_s-cAMP-protein kinase A (PKA) signaling pathway. Treatment with dexamethasone, a potent glucocorticoid, increased GPR65 expression in peritoneal macrophages. Following dexamethasone treatment, there was an inhibition of TNF-α secretion in a manner dependent on increased expression of GPR65. Another report provides an anti-inflammatory role for GPR65 in arthritis. Type II collagen-induced arthritis was increased in GPR65-null mice in comparison to wild-type mice. These studies taken together suggest GPR65 serves as a negative regulator in inflammation. However, one study provided a function for GPR65 as a positive modulator in inflammation. GPR65 was reported to increase eosinophil viability in the acidic microenvironment by reducing apoptosis through the cAMP pathway. As eosinophils are central in asthmatic inflammation and allergic airway disease, GPR65 may play a role in increasing asthmatic inflammation. On the other hand, GPR65 has shown little involvement in immune cell development. One report indicates that GPR65 knockout mice had normal immune development and function. Modulation of inflammation by GPR65 is complex and must be examined within each specific pathology.

In addition to GPR65, GPR4 is also involved in the inflammatory response. Endothelial cells compose blood vessels that often penetrate acidic tissue microenvironments such as the inflammatory loci. Among the pH-sensing GPCR family, GPR4 has the highest expression in endothelial cells. Response to inflammation by vascular endothelial cells facilitates the induction of inflammatory cytokines that are involved in the recruitment of leukocytes for adherence and transmigration into inflamed tissues. Activation of GPR4 by acidosis in human umbilical vein endothelial cells, among other endothelial cell types, increased the expression of a broad range of pro-inflammatory genes including chemokines, cytokines, PTGS2, NF-kB pathway genes, and adhesion molecules. Moreover, human umbilical vein endothelial cells, when treated with acidic pH, increased GPR4-mediated endothelial adhesion to leukocytes. Altogether, GPR65 and GPR4 provide differential regulation of the inflammatory response through their acid sensing capabilities. GPR65 predominately demonstrates function in the inhibition of the inflammatory response whereas GPR4 activation exacerbates inflammation.

**Role for the pH-sensing GPCRs in the cardiovascular system**

The cardiovascular system is essential for the delivery of oxygen and nutrients while also removing metabolic waste from tissues. Vascular occlusion, however, results in tissue ischemia and acidification due to oxygen deprivation, anaerobic metabolism, and deficiency to remove acid byproducts. Within the cardiac system, acidosis disrupts the regulation of action potential duration associated with cardiac excitability. Most notably, this action potential disruption is caused by cardiac ischemia and acidosis, which impairs sodium channels and can lead to life-threatening events such as arrhythmia, myocardial infarction, and cardiac death.

A decrease in interstitial tissue pH may alter angiogenesis. Angiogenesis involves the activation of endothelial cells, which line blood vessels, to switch from a quiescent state to a vascular-sprouting state, giving rise to a functional blood vessel network. This change in active growth can be regulated through signaling by hypoxia, acidosis, VEGF, nitric oxide, among others. A decrease in interstitial tissue pH, which creates an acidic microenvironment, has been attributed to abnormalities in VEGF and VEGF receptor expression and signaling. Furthermore, acidosis may inhibit angiogenesis depending on the extracellular proton concentration.

Disturbances in acid-base balance within the cardiovascular system can also influence vascular tone by modulating endothelial and smooth muscle interactions and function. Intracellular acidosis is associated with vasodilation of large arteries; whereas intracellular acidosis initiates vasoconstriction within smaller arteries noted in the pulmonary vascular system. Additionally, a recent study showed that acidic pH increased relaxation of human placental arteries.

The pH-sensing GPCRs have recently been studied as candidate acid sensors in the cardiovascular system. The GPR4 receptor is highly expressed in vascular endothelial cells. GPR4 is activated by extracellular acidic pH to initiate signaling cascades which regulate cellular function. It has been reported that GPR4 is a functional pH sensor in vascular
endothelial cells and a regulator of blood vessel stability.\(^47\) Whereas adult GPR4-null mice in the C57BL6/129 mixed genetic background were fertile and phenotypically normal, there were smaller litter sizes and a higher perinatal mortality rate in partial correlation with spontaneous hemorrhaging and respiratory distress in a fraction of GPR4-null neonates.\(^47\) Histological analysis revealed GPR4-null neonates with hemorrhages exhibiting disorganized and tortuous blood vessels associated with reduced mural cell coverage.\(^47\) Studies on another GPR4 knockout mouse strain observed that the blood vessels of tumors formed in the GPR4-deficient mice were fragmented and fragile, also suggesting that GPR4 may regulate blood vessel integrity.\(^44\) Similar to the previous study,\(^47\) the phenotype of this GPR4 knockout mouse strain was also grossly normal.\(^44\) However no perinatal mortality was observed in this knockout strain, which might be related to differences in mouse strain genetic backgrounds, knockout constructs, and breeding conditions. Wyder et al also noted that the GPR4-deficient mice showed a reduced angiogenic response to VEGF, implicating the involvement of GPR4 in VEGF-driving angiogenesis.\(^44\) It has been shown that GPR4 activation by acidosis stimulated the expression of endoplasmic reticulum stress response genes such as ATF3 and CHOP (DDIT3) in vascular endothelial cells.\(^32,48\) Moreover, a recent study demonstrated that acidosis/GPR4-induced CHOP expression was involved in endothelial cell apoptosis in a renal ischemia/reperfusion mouse model.\(^49\) These studies provide evidence that implicate involvement of GPR4 in regulating the vascular system.

Another proton-sensing GPCR, GPR68 (OGR1), has also shown involvement in the response of the cardiovascular system to tissue acidosis. Russell et al identified 3,5-disubstituted isoxazoles (lsx), which are cardiomyogenic small molecules targeting Notch activated epicardium-derived cells, as agonists of the GPR68 receptor.\(^50\) GPR68-expressing cardiomyocytes formed a proton-sensing cellular buffer zone surrounding the infarcted myocardium. Activation of GPR68 by lsx induced the expression of cardiomyogenic and pro-survival genes.\(^50\) In human aortic smooth muscle cells, GPR68 is the major receptor responsible for extracellular acidic pH-induced production of inositol phosphate, PGI\(_2\), and cAMP.\(^51\) Additionally, acidic pH-induced vascular actions of aortic smooth muscle cells can be divided into GPR68-dependent effects such as COX-2 expression, PGI\(_2\) production, and MAPK phosphatase-1 expression and GPR68-independent effects such as PAI-1 expression and cell proliferation.\(^52\)

Taken together, both GPR4 and GPR68 play roles in regulating the function of the cardiovascular system. GPR4 regulates blood vessel stability and endothelial cell function and GPR68 increases cardiomyogenic and pro-survival gene expression while also mediating aortic smooth muscle cell gene expression.

**Role for the pH-sensing GPCRs in the renal system**

The human body has several ways to buffer systemic pH to maintain normal physiological homeostasis. The physiological pH of arterial blood is around pH 7.4. Under pathological conditions the body’s blood pH can become acidic (metabolic or respiratory acidosis) or basic (metabolic or respiratory alkalosis). A physiological response to buffer blood pH can occur quickly (minutes) via respiratory activity but may also be modified slowly (days) by controlling the level of extracellular fluid electrolytes through the renal system. Respiratory activity can increase via hyperventilation in response to metabolic acidosis to excrete carbonic acid (H\(_2\)CO\(_3\)) in the form of a gas (CO\(_2\)). When there are excess acids other than CO\(_2\) in the circulatory system the kidneys will excrete them in an effort to restore normal blood pH. Chronic kidney disease among other renal impairments can result in the damage of functioning glomeruli as well as nephrons, which may lead to severe metabolic acidosis. The loss of bases through intestinal bicarbonate malabsorption in the form of diarrhea may also lead to metabolic acidois, which is one of the most common acid/base problems. Metabolic acidosis may lead to poor nutritional status, uremic bone disease, and may correlate with patient mortality.\(^53-55\) In addition, acidosis in the kidney has recently been found to exacerbate the progression of nephropathy.\(^56,57\) As some mechanisms of how circulatory pH may be buffered in response to metabolic acidosis have been discovered, exactly how kidney cells may sense acidosis remains to be fully elucidated. Two of the proton-sensing GPCRs, GPR4 and GPR68, have been studied as pH sensors in the renal system.\(^58,59\) GPR4 and GPR68 are expressed in the lung and kidney, which may both be necessary to successfully buffer the circulatory system and maintain pH homeostasis.

GPR4 is expressed in the kidney cortex, isolated kidney collecting ducts, inner and outer medulla, and in cultured inner and outer medullary collecting duct cells.\(^59\) In mice deficient for GPR4, renal acid excretion and the ability to respond to metabolic acidosis was reduced.\(^59\) In response to acidosis, inner and outer medullary collecting duct cells produced cAMP, a second messenger for the G\(_\text{q}\) G-protein pathway, through the GPR4 receptor.\(^59\) In renal HEK293 epithelial cells GPR4 overexpression was found to increase...
the activity of PKA. In addition, the protein expression of H-\(\text{K}^+\)-ATPase \(\alpha\)-subunit (HK\(\alpha_2\)) was increased following GPR4 overexpression dependent on increased PKA activity.

GPR68 has also been reported to alter proton export of HEK293 cells by stimulating the Na\(^+\)/H\(^+\) exchanger and H\(^+\)-ATPase. The activation of GPR68 by acidosis was found to stimulate this effect through a cluster of extracellular histidine residues and the \(G_{\text{q}}/PKC\) signaling pathway. In GPR68-null mice the expression of the pH-sensitive kinase Pyk2 in the kidney proximal tubules was upregulated which might compensate for GPR68 deficiency. Taken together, GPR4 and GPR68 may both be necessary for successful systemic pH buffering by controlling renal acid excretion.

**Role for the pH-sensing GPCRs in the respiratory system**

The primary function of the respiratory system is to provide an adequate oxygen supply to tissues while subsequently removing carbon dioxide by exhalation. Enhancement of gas transport occurs by hemoglobin binding of oxygen and bicarbonate transport of carbon dioxide. This mechanism maintains an acid/base homeostasis that serves as a required pH buffering system. Respiratory acidosis results from an alteration in the partial pressures of carbon dioxide, a product of cellular metabolism. An increase in carbon dioxide in the blood circulation will facilitate proton accumulation by means of carbonic acid conversion by carbonic anhydrase. Respiratory acidosis has been observed in several respiratory diseases, such as chronic obstructive pulmonary disease (COPD) and asthma.

Asthma is a chronic inflammatory disease, which is associated with bronchial hyper-responsiveness, airway inflammation, remodeling, and acidic features. Ichimonji et al demonstrated in human airway smooth muscle cells that GPR68 mediated extracellular acidification-induced production of pro-inflammatory cytokine IL-6 and increased intracellular Ca\(^{2+}\) concentration. The same group also found that extracellular acidification of pH 6.3 induced the expression of CTGF, which was involved in the formation of extracellular matrix proteins and associated with airway remodeling, through the GPR68/G\(_{\text{q11}}\)/IP\(_1\)/Ca\(^{2+}\) pathway. Furthermore, Saxena et al demonstrated that GPR68 receptor mediated airway smooth muscle cell contraction in an acidic extracellular environment. Inflammatory airway disease is also known to have excess mucus excretion, which can be exacerbated by exposure to an acidic microenvironment. Liu et al showed that airway acidification could induce the hyper-secretion of MUC5AC, a protein associated with mucus production within the pulmonary tracts, in human airway epithelial cells.

Aoki et al demonstrated that GPR68-deficient mice were resistant to asthma along with inhibiting Th2 cytokine and immunoglobulin E production. This study concludes that GPR68 in dendritic cells is crucial for the onset of asthmatic responses. Moreover, GPR65 has been implicated as having a role in respiratory disorders as it is highly expressed in eosinophils, hallmark cells for asthmatic inflammation. Kottyan et al showed that GPR65 increased the viability of eosinophils within an acidic environment through the cAMP pathway in murine asthma models. In summary, GPR68 and GPR65 play important roles in the respiratory system and asthma. GPR68 regulates gene expression in airway epithelial, smooth muscle and immune cells while GPR65 enhances the survival of airway eosinophils in response to acidosis.

**Role for the pH-sensing GPCRs in the skeletal system**

Recently, pH-sensing GPCRs have been found to be important for response to metabolic acidosis in the skeletal system. During metabolic acidosis there are several mechanisms to restore normal physiological pH as mentioned previously. In addition to respiratory CO\(_2\) excretion and renal acid excretion, the skeletal system also carefully balances systemic pH. Acidosis has been reported to directly inhibit osteoblast activity, resulting in a reduction in the bone resorbing of minerals and Ca\(^{2+}\). Acidosis may also activate osteoclast activity to increase Ca\(^{2+}\) release in vitro. Calcium release and mineral dissolution from bone may help systemically buffer protons and restore normal physiological pH. Chronic metabolic acidosis can result in a reduction of total volumetric bone density and over time can result in osteoporosis. The reduction in osteoblast activity may also reduce the gene expression of several matrix proteins such as COL1A, OPN, and MGP, which may contribute to increased osteoarthritis development. Two of the pH-sensing G protein-coupled receptors, GPR68 and GPR65, have been reported to sense acidosis in bone cells.

Among other cell types, there is high expression of GPR68 in osteoblasts and osteoclasts as well as chondrocytes. As osteoclast and osteoblast homeostasis may regulate systemic pH by controlling the release of minerals from bone, GPR68 has been speculated as a possible bone acidosis sensor. In addition, GPR68 is expressed during osteoclastogenesis and may be involved in osteoclast differentiation. Acidosis
has been determined to increase the accumulation of NFATc1 protein through NF-kappa B ligand (RANKL) in the nuclei of rat and rabbit osteoclasts.74 This was proposed to occur through prolonged Ca\(^{2+}\) release and the sequential activation of the calcineurin/NFAT pathway in response to GPR68 activation by acidosis.75 In normal human osteoblast (NHOst) cells acidosis has been found to stimulate the expression of COX2 and PGE\(_2\) through the GPR68-mediated G\(_q/11\)/PLC/Ca\(^{2+}\) signaling pathway.76 GPR68 is also expressed in cultured neonatal calvariae osteoblasts and in response to acidosis may increase intracellular Ca\(^{2+}\) release.77 Furthermore, following the transfection of a heterologous GPR68 construct into Chinese hamster ovary cells, the response to acidosis stimulated the intracellular release of Ca\(^{2+}\) as well.76 GPR68 expression in rat endplate chondrocytes was found to induce apoptosis in response to acidosis,80 which could reduce collagen production and lead to intervertebral disk degeneration.

GPR65 has also been reported as a pH sensor in bone. GPR65 is expressed in osteoclasts and its activity may inhibit Ca\(^{2+}\) resorption.81 Disruption of GPR65 gene exacerbated osteoclastic bone resorption in ovariectomized mice.81 The relative bone density of GPR65-null mice was less than control mice.81 In cultured osteoclasts from mice deficient for GPR65, the normal inhibition of osteoclast formation in response to acidosis was abrogated.81 Taken together, this data suggest that the activation of GPR65 may enhance bone density, thus the GPR65 signaling may be important for disease processes such as osteoporosis and other bone density disorders.

**Role for the pH-sensing GPCRs in the endocrine system**

The effects of metabolic acidosis have been studied in the endocrine system. Metabolic acidosis can alter insulin secretion as well as pancreatic function,82 which is relevant in disease states such as diabetes. Recently, the pH-sensing GPCRs, GPR4 and GPR68, have been found to be involved in insulin secretion and tissue sensitivity to insulin.83,84 In GPR4 knockout mice glucose tolerance was augmented by increasing the sensitivity to insulin.83 The balance of pro-inflammatory and anti-inflammatory molecules are crucial for the maintenance of insulin sensitivity as pro-inflammatory cytokines can further promote insulin resistance and type II diabetes.85 The absence of GPR4 may reduce the expression of several inflammatory modulators in white adipose tissue such as IL-6 and PPAR\(\alpha\) and an increase in TNF-\(\alpha\) and TGF1-\(\beta\).83 GPR4 is also highly expressed in endothelial cells, which when activated has been reported to stimulate the expression of inflammatory genes.82,83

GPR68 has also been found to modify insulin production and secretion. In GPR68 knockout mice insulin secretion in response to glucose administration was reduced when compared to wild-type mice although blood glucose was not significantly altered.84 GPR68 deficiency in this respect may reduce insulin secretion but at the same time increase insulin sensitivity. In addition, stimulation of GPR68 in islet cells by acidosis increased the secretion of insulin through the G\(_{q/11}\) G-protein signaling.84

**Role for the pH-sensing GPCRs in the nervous system and nociception**

Acidosis causes pain by exciting nociceptors located in sensory neurons. Several types of ion channels and receptors, such as ASICs, TRPV1, and proton-sensing GPCRs, have been identified as nociceptors in response to acidosis. ASICs and TRPV act as proton-gated membrane-bound channels, which are activated by acidic pH and mediate multimodal sensory perception including nociception.86-88 It has also been reported that acidosis causes excitation or modulation of nociceptive sensory neurons through proton-sensing GPCRs.89 All proton-sensing GPCRs are localized in the dorsal root ganglia that are the pain-relevant loci.89 Chen et al demonstrated the involvement of GPR65 in inflammatory pain by using mouse models with injection of capsaicin, carrageenan, and complete Freund’s adjuvant.89 Notably, GPR65 activation sensitized the response of TRPV1 to capsaicin. The results suggest high accumulation of protons post inflammation may not only stimulate nociceptive ion channels such as TRPV1 to trigger pain, but also activate proton-sensing GPCRs to regulate heightened sensitivity to pain.89 Furthermore, Hang et al demonstrated GPR65 activation elicited cancer-related bone pain through the PKA and phosphorylated CREB (pCREB) signaling pathway in the rat model.90 Collectively, GPR4, GPR65, and GPR68 are all expressed in the dorsal root ganglia; GPR65 is a functional receptor involved in nociception and the nervous system by sensitizing inflammatory pain and the evocation of cancer-related bone pain.

**Role for the pH-sensing GPCRs in tumor biology**

The tumor microenvironment is highly heterogeneous. Hypoxia, acidosis, inflammation, defective vasculature, poor blood perfusion, and deregulated cancer cell metabolism are hallmarks of the tumor microenvironment.91-93 The acidity
in the tumor microenvironment is owing to the altered cancer cell metabolism termed the “Warburg Effect”. This metabolic phenotype allows the cancer cells to preferentially utilize glycolysis over oxidative phosphorylation as a primary means of energy production. This process occurs even in normoxic tissue environments where sufficient oxygen is available. Due to this phenomenon, the Warburg Effect is often termed “aerobic glycolysis”. This unique metabolic phenotype produces vast quantities of lactic acid, which serve as a proton source for acidification. Upon disassociation of lactic acid to one lactate molecule and one proton, the monocarboxylate transporter and proton transporters export lactate and protons into the extracellular tumor microenvironment. The proton-sensing GPCRs are activated by acidic pH and facilitate tumor cell modulation in response to extracellular acidification. GPR4, GPR65, and GPR68 play roles in tumor cell apoptosis, proliferation, metastasis, angiogenesis, and immune cell function.

GPR4 has had conflicting reports in terms of tumor suppressor or promoting activities. One study demonstrated that GPR4 could act as a tumor metastasis suppressor, when overexpressed and activated by acidic pH in B16F10 melanoma cells, by impeding migration and invasion of tumor cells. GPR4 overexpression also significantly inhibited the lung metastasis of B16F10 melanoma cells in mice. Another study utilizing the B16F10 melanoma cell line which overexpressed GPR4 showed an increase in mitochondrial surface area and a significant reduction in membrane protrusions by quantification of 3D morphology. These data point to a decrease in cancer cell migration when GPR4 is overexpressed and provides another example of GPR4 as exhibiting tumor metastasis suppressor function. However, in another report GPR4 malignantly transformed immortalized NIH3T3 fibroblasts. This presents GPR4 with tumor-promoting capabilities. The conflicting reports seem to indicate the functional ability of GPR4 to act as a tumor promoter and a tumor suppressor depending on the context of certain cell types and biological systems.

Reports with GPR65 involvement in cancer cells provide evidence in favor for cancer cell survival; however, opposing evidences suggest GPR65 functions as a tumor suppressor. In the same report suggesting GPR4 is oncogenic due to GPR4 transforming immortalized NIH3T3 fibroblasts, GPR65 overexpression was able to transform the mouse NMuMG mammary epithelial cell line. Another group demonstrated in NCI-H460 human non-small cell lung cancer cells that GPR65 promotes cancer cell survival in an acidic microenvironment. Conversely, a recent study showed that GPR65 inhibited c-Myc oncogene expression in human lymphoma cells. Furthermore, GPR65 messenger ribonucleic acid expression was reduced by more than 50% in a variety of human lymphoma samples when compared to normal lymphoid tissues, therefore implying GPR65 has a tumor suppressor function in lymphoma. GPR65 has also been shown to increase glucocorticoid-induced apoptosis in murine lymphoma cells. These reports highlight cell type dependency and biological context for GPR65 activity as a tumor suppressor or promoter.

GPR68 also has roles in tumor biology as a potential tumor suppressor or a tumor promoter. Reports have shown that GPR68 can inhibit cancer metastasis, reduce cancer cell proliferation, and inhibit migration. One study showed that when GPR68 was overexpressed in prostate cancer cells, metastasis to the lungs, diaphragm, and spleen was inhibited. Another study reported GPR68 expression was critical for the tumor cell induced immunosuppression in myeloid-derived cells. This study proposed that GPR68 promotes M2 macrophage development and inhibits T-cell infiltration, and thereby facilitates tumor development. In summary, the biological roles of GPR4, GPR65, and GPR68 in tumor biology are complex and both tumor-suppressing and tumor-promoting functions have been reported, primarily dependent on cell type and biological milieu.

**Development of small molecule modulators of the pH-sensing GPCRs**

GPCRs are critical receptors for the regulation of many physiological operations. It is of little surprise that GPCRs have become a central focus of pharmaceutical development. In fact, 30%–50% of therapeutics focuses on modulating GPCR activity. In view of the diverse roles of the pH-sensing GPCRs in the context of multiple biological systems, targeting these receptors with small molecules and other modulators could serve as potential therapeutics for diseases associated with deregulated pH homeostasis. There have been recent developments in the characterization of GPR4 antagonists along with agonists for GPR65 and GPR68. The GPR4 antagonist demonstrated effectiveness in vitro to reduce the GPR4-mediated inflammatory response to acidosis in endothelial cells. The GPR65
agonist, BTB09089, showed in vitro effects in GPR65 activation of immune cells to inhibit inflammatory response; however, the activity of BTB09089 was not strong enough for the use in animal models in vivo.\textsuperscript{29} The GPR68 agonist, lsx, exhibited pro-neurogenic activity and induced hippocampal neurogenesis in young mice.\textsuperscript{107} It was also demonstrated that lsx suppressed the proliferation of malignant astrocytes.\textsuperscript{108} To date, however, much advancement needs to be done in development of efficacious agonists and antagonists of the pH-sensing GPCRs coupled with a capacity to target specific tissue dysfunction in the midst of systemic drug administration to optimize therapeutic effects and minimize potential adverse effects.

**Concluding remarks**

Cells encounter acidic stress in many pathophysiologic conditions such as inflammation, cancer, and ischemia. Intricate molecular mechanisms, including a large array of acid/base transporters and acid sensors, have evolved for cells to sense and respond to acidic stress. Emerging evidence has demonstrated that a family of the pH-sensing GPCRs can be activated by extracellular acidic stress and regulate the function of multiple physiological systems (Table 1). The pH-sensing GPCRs also play important roles in various pathological disorders. Agonists, antagonists and other modulators of the pH-sensing GPCRs are being actively developed and evaluated as potential novel treatment for acidosis-related diseases.

**Acknowledgments**

The research in the authors’ laboratory was supported in part by grants from the American Heart Association National Center, Brody Brothers Endowment Fund, Brody School of Medicine Seed Grant, Golfers against Cancer Foundation, North Carolina Biotechnology Center, and Vidant Medical Center Cancer Research and Education Fund (to LVY).

---

**Table 1 The main biological functions of the pH-sensing GPCRs**

<table>
<thead>
<tr>
<th>System</th>
<th>GPR65 (TDAG8)</th>
<th>GPR4</th>
<th>GPR68 (OGR1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immune and inflammation</td>
<td>Inhibits pro-inflammatory cytokine secretion in macrophages and suppresses inflammatory response in mice.\textsuperscript{23,27–29}</td>
<td>Induces inflammatory gene expression in response to acidosis in endothelial cells.\textsuperscript{32}</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td>Enhances eosinophil survival under acidosis.\textsuperscript{31}</td>
<td>Increases leukocyte-endothelial cell adhesion.\textsuperscript{21,22}</td>
<td>Increases expression of cardiomyogenic and pro-survival genes in the heart; as well as mediates gene expression in aortic smooth muscle cells.\textsuperscript{75–77}</td>
</tr>
<tr>
<td>Cardiovascular</td>
<td>N/A</td>
<td>Regulates blood vessel stability and integrity.\textsuperscript{44,47}</td>
<td>Increases expression of cardiomyogenic and pro-survival genes in the heart; as well as mediates gene expression in aortic smooth muscle cells.\textsuperscript{75–77}</td>
</tr>
<tr>
<td>Renal</td>
<td>N/A</td>
<td>Regulates renal acid excretion in mice and H+\textsuperscript{+}-K\textsuperscript{-}-ATPase expression.\textsuperscript{59,60}</td>
<td>Regulates proton transporter activity and proton extrusion in the kidney.\textsuperscript{58}</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Implicated in asthmatic inflammation.\textsuperscript{21}</td>
<td>N/A</td>
<td>Regulates gene expression and airway smooth muscle cell contraction.\textsuperscript{64–67}</td>
</tr>
<tr>
<td>Skeletal</td>
<td>Inhibits osteoclastic bone resorption; relative bone density is reduced in GPR65-null mice.\textsuperscript{81}</td>
<td>N/A</td>
<td>GPR68-null mice are resistant to asthma.\textsuperscript{48}</td>
</tr>
<tr>
<td>Endocrine</td>
<td>N/A</td>
<td>Regulates inflammatory gene expression in insulin target tissues; insulin sensitivity is increased in GPR4-null mice.\textsuperscript{87}</td>
<td>GPR68 activation by acidosis stimulates apoptosis in chondrocytes.\textsuperscript{89}</td>
</tr>
<tr>
<td>Nervous/</td>
<td>Sensitizes inflammatory pain and cancer-related bone pain.\textsuperscript{89,90}</td>
<td>Overexpression inhibits B16F10 melanoma cell migration, invasion, and metastasis.\textsuperscript{15,50}</td>
<td>Increases insulin secretion in response to acidosis.\textsuperscript{84}</td>
</tr>
<tr>
<td>Tumor biology</td>
<td>Transforms NMuMG mammary epithelial cell line.\textsuperscript{79}</td>
<td>Overexpression inhibits proliferation of malignant astrocytes.\textsuperscript{108}</td>
<td>Overexpression in prostate cancer cells suppresses metastasis to lungs, diaphragm, and spleen in mice.\textsuperscript{97}</td>
</tr>
<tr>
<td></td>
<td>Inhibits c-Myc oncogene expression in human lymphoma cells.\textsuperscript{101}</td>
<td>Overexpression transforms immortalized NIH3T3 fibroblasts.\textsuperscript{99}</td>
<td>Overexpression inhibits ovarian cancer cell proliferation and migration.\textsuperscript{96}</td>
</tr>
<tr>
<td></td>
<td>Enhances glucocorticoid-induced apoptosis in murine lymphoma cells.\textsuperscript{102}</td>
<td></td>
<td>Induces immunosuppression and promotes tumor development in mice.\textsuperscript{103}</td>
</tr>
</tbody>
</table>

**Abbreviations**: GPCRs, G protein-coupled receptors; N/A, not available.
**Disclosure**

Dr Li Yang is the inventor of a US patent (US 8207139 B2) “Function of GPR4 in vascular inflammatory response to acidosis and related methods”, but there is no current financial interest. The authors report no conflicts of interest in this work.

**References**

5. De Vito P. The sodium/hydrogen exchanger: a possible mediator of acidicosis and related methods, but there is no current financial interest. The authors report no conflicts of interest in this work.

6. De Vito P. The sodium/hydrogen exchanger: a possible mediator of acidosis and related methods, but there is no current financial interest. The authors report no conflicts of interest in this work.

7. Fang J, Quinones QJ, Holman TL, et al. The H^+ to acidosis and related methods, but there is no current financial interest. The authors report no conflicts of interest in this work.

8. Fang J, Quinones QJ, Holman TL, et al. The H^+ to acidosis and related methods, but there is no current financial interest. The authors report no conflicts of interest in this work.

9. Fang J, Quinones QJ, Holman TL, et al. The H^+ to acidosis and related methods, but there is no current financial interest. The authors report no conflicts of interest in this work.

10. Fang J, Quinones QJ, Holman TL, et al. The H^+ to acidosis and related methods, but there is no current financial interest. The authors report no conflicts of interest in this work.

11. Fang J, Quinones QJ, Holman TL, et al. The H^+ to acidosis and related methods, but there is no current financial interest. The authors report no conflicts of interest in this work.

12. Fang J, Quinones QJ, Holman TL, et al. The H^+ to acidosis and related methods, but there is no current financial interest. The authors report no conflicts of interest in this work.

13. Fang J, Quinones QJ, Holman TL, et al. The H^+ to acidosis and related methods, but there is no current financial interest. The authors report no conflicts of interest in this work.

14. Fang J, Quinones QJ, Holman TL, et al. The H^+ to acidosis and related methods, but there is no current financial interest. The authors report no conflicts of interest in this work.

15. Fang J, Quinones QJ, Holman TL, et al. The H^+ to acidosis and related methods, but there is no current financial interest. The authors report no conflicts of interest in this work.

16. Fang J, Quinones QJ, Holman TL, et al. The H^+ to acidosis and related methods, but there is no current financial interest. The authors report no conflicts of interest in this work.

17. Fang J, Quinones QJ, Holman TL, et al. The H^+ to acidosis and related methods, but there is no current financial interest. The authors report no conflicts of interest in this work.

18. Fang J, Quinones QJ, Holman TL, et al. The H^+ to acidosis and related methods, but there is no current financial interest. The authors report no conflicts of interest in this work.

19. Fang J, Quinones QJ, Holman TL, et al. The H^+ to acidosis and related methods, but there is no current financial interest. The authors report no conflicts of interest in this work.

20. Fang J, Quinones QJ, Holman TL, et al. The H^+ to acidosis and related methods, but there is no current financial interest. The authors report no conflicts of interest in this work.

21. Fang J, Quinones QJ, Holman TL, et al. The H^+ to acidosis and related methods, but there is no current financial interest. The authors report no conflicts of interest in this work.

22. Fang J, Quinones QJ, Holman TL, et al. The H^+ to acidosis and related methods, but there is no current financial interest. The authors report no conflicts of interest in this work.

23. Fang J, Quinones QJ, Holman TL, et al. The H^+ to acidosis and related methods, but there is no current financial interest. The authors report no conflicts of interest in this work.

24. Fang J, Quinones QJ, Holman TL, et al. The H^+ to acidosis and related methods, but there is no current financial interest. The authors report no conflicts of interest in this work.

25. Fang J, Quinones QJ, Holman TL, et al. The H^+ to acidosis and related methods, but there is no current financial interest. The authors report no conflicts of interest in this work.


